BMS Sell API Facility to SK Biotek

News
Article

SK Biotek plans to operate the Swords, Ireland API manufacturing facility as a contract development and manufacturing site.

SK Biotek Co., Ltd, a wholly-owned subsidiary of SK Holdings, will be the first Korean company to invest in pharmaceutical manufacturing in Ireland with the announced acquisition of the Bristol-Myers Squibb’s small-molecule API manufacturing facility in Swords, Ireland. The companies announced the acquisition in a June 16, 2017 statement.

The companies have an existing pharmaceutical manufacturing and supply relationship; SK Biotek has produced commercial API starting materials and chemical intermediates for BMS.

The Swords facility manufactures APIs for medicines including Bristol-Myers Squibb’s and Pfizer’s Eliquis. SK Biotek announced plans to operate the plant as a contract development manufacturing organization (CDMO), add marketing and R&D staff, and invest in additional capacity.

“This transaction is an important step to achieve our goal of becoming a leading global CDMO.” Junku Park, chief executive officer of SK Biotek, commented in the statement. “It allows us to enhance technological and manufacturing capacity and build long-term partnerships with existing and new customers. We have chosen to invest in Ireland because of the welcoming business environment and the exceptionally talented workforce, and we look forward to growing our presence in Swords in the coming years. We are very pleased to welcome the Swords facility to SK Biotek.”

Bristol-Myers Squibb and SK Biotek anticipate that the transaction will close during the fourth quarter of 2017, subject to certain environmental permits and other customary closing conditions. The transaction has been approved by the boards of directors of both companies.

Source: Bristol-Myers Squibb

 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content